- Zacks•4 hours ago
Keryx???s fourth-quarter 2016 loss was wider-than-expected. The company posted a loss of 32 cents per share wider than consensus estimate of a loss of 27 cents.
- Associated Press•6 hours ago
The Boston-based company said it had a loss of 32 cents per share. The results did not meet Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for ...
- GlobeNewswire•6 hours ago
Fourth quarter and Full Year 2016 Auryxia ® net U.S. product sales of $8.2 million and $27.2 million, respectively Early 2017 Auryxia prescription demand showing positive momentum and outperformed overall ...
KERX : Summary for Keryx Biopharmaceuticals, Inc. - Yahoo Finance
Keryx Biopharmaceuticals, Inc. (KERX)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||5.08 x 1200|
|Ask||5.09 x 800|
|Day's Range||4.92 - 5.45|
|52 Week Range||3.99 - 7.80|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-3.25|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|